Crohn's Disease and Colitis Trial, Recruiting NCT05733845 Sponsor: Central Hospital, Nancy, France Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Crohn's Disease and Colitis Trial, Recruiting

NCT05733845
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older
  • You have been fully informed about the study and have signed a consent form agreeing to take part
  • You have a confirmed diagnosis of Crohn's disease or ulcerative colitis, and you have had the condition for at least 3 months
  • Your disease is considered moderate to severe based on specific scoring systems used by your doctor (confirm with trial site)
  • Your doctor has decided you should start a biological therapy or a type of medication called a small molecule agent (such as anti-TNF, anti-integrin, anti-IL 12/23, or JAK-inhibitor treatments)
  • If you are taking corticosteroids (like prednisone), your dose has been stable for at least 3 weeks before the study starts and is no higher than 20 mg of prednisone per day
  • You already need a colonoscopy as part of your usual care to check how active your disease is
  • You are covered by a social security or health insurance plan (this appears to be a French healthcare requirement — confirm with trial site)

Who may not be able to join:

  • You have been diagnosed with a different type of colitis, such as indeterminate colitis, microscopic colitis, ischaemic colitis, infectious colitis, or radiation colitis
  • You have a medical reason why you cannot safely have a colonoscopy, or you had a serious complication during a previous colonoscopy
  • You have a bleeding disorder
  • You need surgery for your ulcerative colitis
  • You have used rectal treatments such as enemas or suppositories within the 2 weeks before the study starts
  • You have been taking more than 20 mg of prednisone within the 3 weeks before the study starts
  • You have anaemia (low red blood cell levels, specifically haemoglobin below 10 g/dl) at the start of the study
  • You are unable to follow or participate in the study procedures for any reason
  • You are pregnant, currently giving birth, or breastfeeding
  • You are under 18 years old or are a minor in legal terms
  • You are an adult under a form of legal guardianship or protection
  • You are an adult who is unable to give informed consent and is not under legal protection
  • You are currently deprived of your liberty by a legal or administrative decision, or you are receiving certain forms of involuntary psychiatric care

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
14 June 2023
Est. completion
1 August 2030

Where this trial is recruiting

🇫🇷 France

Primary endpoints

To identify solid biomarkers signatures as well as molecular pathways and mechanisms linked to response and non-response to therapy in ulcerative colitis patient.; To identify solid biomarkers signatures as well as molecular pathways and mechanisms linked to response and non-response to therapy in Crohn's disease patient.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov